EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Pharmacokinetics and Safety of VV116 in Subjects With Mild or Moderate Hepatic Impairment Compared With Healthy Controls: A Phase I, Open‐Label Study

Xi Tan, Tong Lu, Shijuan Kuang, Qin Meng, Ge Yu, Jianjun Zou, Yuya Wang

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70037 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Xi Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, China. Hauptthemen laut MEDLINE: Adenosine, Antiviral Agents, COVID-19 Drug Treatment, Liver Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Junshi Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VV116 (Mindvy, JT001) is a deuterated oral derivative of remdesivir hydrobromide developed for the treatment of COVID‐19. Because hepatic dysfunction may influence drug exposure, this Phase 1, open‐label, parallel‐group study characterized the pharmacokinetics and safety of VV116 in adults with mild or moderate hepatic impairment (classified by the Child–Pugh method) compared with matched healthy controls. Each participant received a single oral 0.3‐g dose of VV116 under fasting conditions, and serial plasma samples were collected through 72 h to quantify VV116 and its active metabolite, 116‐N1, by validated LC‐MS/MS. Overall exposure (AUC) in mild and moderate impairment was comparable to controls (AUC 0‐t GMRs 94.10% [90% CI 71.59%‐123.68%] and 97.72% [74.34%‐128.44%]), with similar median T max and t 1/2 ; C max was lower in both impairment cohorts. Treatment‐emergent adverse events occurred in 12.5% (mild), 37.5% (moderate), and 12.5% (control) groups; all were mild or moderate, transient, and resolved without treatment. The higher incidence in the moderate group was not considered clinically meaningful, as events were isolated and not related to VV116 exposure. No serious adverse events, deaths, or discontinuations occurred. Overall, hepatic impairment had no clinically relevant effect on VV116 pharmacokinetics, and dose adjustment appears unnecessary for patients with mild or moderate hepatic impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenosineAntiviral AgentsCOVID-19 Drug TreatmentLiver DiseasesAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralArea Under CurveSeverity of Illness Index

Stichwörter der Autor:innen

COVID‐19VV116hepatic impairmentnucleoside analogpharmacokineticssafety

Substanzen

AdenosineAntiviral AgentsGS-621763

Autor:innen und Institutionen

  • Research and Development Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, China.

Förderung

  • Junshi Biosciences

Zitieren

APA

Tan, X., Lu, T., Kuang, S., Meng, Q., Yu, G., Zou, J., & Wang, Y. (2026). Pharmacokinetics and Safety of VV116 in Subjects With Mild or Moderate Hepatic Impairment Compared With Healthy Controls: A Phase I, Open‐Label Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70037

Vancouver

Tan X, Lu T, Kuang S, Meng Q, Yu G, Zou J, et al. Pharmacokinetics and Safety of VV116 in Subjects With Mild or Moderate Hepatic Impairment Compared With Healthy Controls: A Phase I, Open‐Label Study. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70037

BibTeX
@article{Tan2026,
  author = {Tan, Xi and Lu, Tong and Kuang, Shijuan and Meng, Qin and Yu, Ge and Zou, Jianjun and Wang, Yuya},
  title = {Pharmacokinetics and Safety of VV116 in Subjects With Mild or Moderate Hepatic Impairment Compared With Healthy Controls: A Phase I, Open‐Label Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70037}
}
Kostenlos starten →